Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

CROI 2025 will cover viral infections, treatments, and potential cures, focusing on HIV, COVID-19, STIs, and hepatitis C. The conference will feature plenary sessions on HIV research, global ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and ...

AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full day of the conference, reports from the ...

To learn more, please visit www.reprievetrial.org.

A study presented at CROI 2025 reveals that a single-question self-efficacy measure effectively predicts ART adherence and viral load suppression among pregnant women with HIV in Malawi, offering a ...

(Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the ...